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Background—The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced 
ejection fraction are not known. We investigated these in the Prospective Comparison of ARNI With ACEI to Determine 
Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial.
Methods and Results—We examined clinical outcomes in 8399 patients with heart failure and reduced ejection fraction 
according to history of diabetes mellitus and glycemic status (baseline hemoglobin A1c [HbA1c]: <6.0% [<42 mmol/
mol], 6.0%–6.4% [42–47 mmol/mol; pre–diabetes mellitus], and ≥6.5% [≥48 mmol/mol; diabetes mellitus]), in Cox 
regression models adjusted for known predictors of poor outcome. Patients with a history of diabetes mellitus (n=2907 
[35%]) had a higher risk of the primary composite outcome of heart failure hospitalization or cardiovascular mortality 
compared with those without a history of diabetes mellitus: adjusted hazard ratio, 1.38; 95% confidence interval, 1.25 to 
1.52; P<0.001. HbA1c measurement showed that an additional 1106 (13% of total) patients had undiagnosed diabetes 
mellitus and 2103 (25%) had pre–diabetes mellitus. The hazard ratio for patients with undiagnosed diabetes mellitus 
(HbA1c, >6.5%) and known diabetes mellitus compared with those with HbA1c<6.0% was 1.39 (1.17–1.64); P<0.001 
and 1.64 (1.43–1.87); P<0.001, respectively. Patients with pre–diabetes mellitus were also at higher risk (hazard ratio, 
1.27 [1.10–1.47]; P<0.001) compared with those with HbA1c<6.0%. The benefit of LCZ696 (sacubitril/valsartan) 
compared with enalapril was consistent across the range of HbA1c in the trial.
Conclusions—In patients with heart failure and reduced ejection fraction, dysglycemia is common and pre–diabetes mellitus 
is associated with a higher risk of adverse cardiovascular outcomes (compared with patients with no diabetes mellitus and 
HbA1c <6.0%). LCZ696 was beneficial compared with enalapril, irrespective of glycemic status.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.   
(Circ Heart Fail. 2016;9:e002560. DOI: 10.1161/CIRCHEARTFAILURE.115.002560.)
Key Words: clinical trial ■ diabetes mellitus ■ heart failure ■ prognosis ■ treatment outcome
Received June 1, 2015; accepted November 6, 2015.
From the British Heart Foundation, Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (S.L.K., D.P., P.J., J.J.V.M.); 
Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark (S.L.K.); Department of Cardiovascular Sciences, University of Leicester, 
Leicester, UK (I.S.); NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, UK (I.S.); Department of Cardiology, Porto Medical 
School, Porto, Portugal (J.S.C.); Heart and Vascular Center Semmelweiss University, Budapest, Hungary (B.M.); Instituo DAMIC, Cordoba National 
University, Cordoba, Argentina (F.M.); Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, OH (R.C.S.); Division of 
Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA (A.S.D); Novartis Pharmaceutical Corporation, East Hanover, NJ (M.P.L., A.R.R., 
V.C.S.); Institut de Cardiologie, Université de Montréal, Montréal, Québec, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of 
Gothenburg, Gothenburg, Sweden (K.S.); RHJ Department of Veterans Administration Medical Center, Medical University of South Carolina, Charleston 
(M.R.Z.); and Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas (M.P.).
*A list of all PARADIGM-HF Investigators and Committees is given in the Appendix.
Guest Editor for this article was Gregg C. Fonarow, MD. 
Correspondence to John J.V. McMurray, MD, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Pl, 
Glasgow, G12 8TA, United Kingdom. E-mail john.mcmurray@glasgow.ac.uk
Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus 
in Heart Failure With Reduced Ejection Fraction
Insights From Prospective Comparison of ARNI With ACEI to Determine 
Impact on Global Mortality and Morbidity in Heart Failure Trial
Søren L. Kristensen, MD, PhD; David Preiss, MD, PhD; Pardeep S. Jhund, MB, PhD;  
Iain Squire, MD; José Silva Cardoso, MD, PhD; Bela Merkely, MD, PhD, DSc;  
Felipe Martinez, MD; Randall C. Starling, MD, MPH; Akshay S. Desai, MD;  
Martin P. Lefkowitz, MD; Adel R. Rizkala, PharmD; Jean L. Rouleau, MD; Victor C. Shi, MD;  
Scott D. Solomon, MD; Karl Swedberg, MD; Michael R. Zile, MD; John J.V. McMurray, MD;  
Milton Packer, MD; for the PARADIGM-HF Investigators and Committees*
2  Kristensen et al  Pre–Diabetes Mellitus and Diabetes Mellitus in PARADIGM-HF
Heart failure and type 2 diabetes mellitus are 2 of the great epidemics of modern times.1,2 Although each begets the 
other, the links between the 2 conditions are not fully elucidated.3 
Although it is widely acknowledged that diabetes mellitus is a risk 
marker for the development of heart failure and greatly height-
ens the risk of worse outcomes once heart failure develops,4–6 the 
relationship between heart failure and the development of diabetes 
mellitus is less well understood. Although heart failure seems to 
be a state of insulin resistance, the mechanisms underlying this 
are not clear.7 Few studies have investigated the prevalence of 
pre–diabetic dysglycemia in patients with heart failure and even 
fewer its clinical consequences (and with conflicting findings).8,9 
Identification of an association, if any, between pre–diabetes 
mellitus and adverse clinical outcomes is of clinical importance 
from 2 contrasting perspectives. There has been recent concern 
that hypoglycemic agents might contribute to the poor cardiovas-
cular outcomes, including heart failure, in patients with diabetes 
mellitus.3 Demonstration that patients with pre–diabetes mellitus, 
untreated with hypoglycemic agents, have worse outcomes than 
normoglycemic patients would support the view that dysglycemia 
per se is harmful in heart failure. If so, treatment of such patients 
with hypoglycemic agents might prevent the development of dia-
betes mellitus and improve heart failure outcomes. We, therefore, 
investigated the prevalence of diabetes mellitus and pre–diabetes 
mellitus in patients with heart failure and reduced ejection frac-
tion (HF-REF) who participated in the Prospective Comparison of 
ARNI With ACEI to Determine Impact on Global Mortality and 
Morbidity in Heart Failure (PARADIGM-HF) trial10 and examined 
the relationship between glycemic status and clinical outcomes 
in this trial. We also compared the effect of sacubitril/valsartan 
(LCZ696) with enalapril in patients in the PARADIGM-HF trial 
according to glycemic status.
Methods
The design and primary results of the PARADIGM-HF trial have 
been described in detail.10–12
The trial was approved by the ethics committee at each study cen-
ter. All the patients provided written informed consent.
Study Patients
The inclusion criteria for the PARADIGM-HF trial included New York 
Heart Association class II–IV symptoms, EF ≤40% (changed to ≤35% 
by amendment), and a plasma B-type natriuretic peptide (BNP) ≥150 
pg/mL (or N-terminal pro-BNP, ≥600 pg/mL). Patients who had been 
hospitalized for heart failure within the preceding 12 months could be 
enrolled with a lower natriuretic peptide concentration (BNP, ≥100 pg/
mL or N-terminal pro-BNP, ≥400 pg/mL). Patients were required to 
be taking an angiotensin-converting enzyme inhibitor or angiotensin 
receptor blocker at a dose equivalent to enalapril 10 mg daily for at 
least 4 weeks before screening, along with a stable dose of a β-blocker 
(unless contraindicated or not tolerated) and a mineralocorticoid recep-
tor antagonist, if indicated. The exclusion criteria included history of 
intolerance of an angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker, symptomatic hypotension (or a systolic blood 
pressure, <100 mm Hg at screening/<95 mm Hg at randomization), 
an estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 
m2, a serum potassium concentration >5.2 mmol/L at screening (>5.4 
mmol/L at randomization), or a history of angioedema.
Study Procedures
On trial entry, existing treatment with an angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker was stopped, but 
other treatments for heart failure were continued. Patients first re-
ceived enalapril 10 mg twice daily for 2 weeks (single-blind) and then 
LCZ696 (single-blind) for an additional 4 to 6 weeks, initially at 100 
mg twice daily and then 200 mg twice daily. Patients tolerating both 
drugs at target doses were randomly assigned in a 1:1 ratio to double-
blind treatment with either enalapril 10 mg twice daily or LCZ696 
200 mg twice daily. The dose of enalapril was selected based on its ef-
fect to reduce the risk of death compared with placebo in the Studies 
of Left Ventricular Dysfunction (SOLVD) treatment trial.13 LCZ696 
200 mg twice daily delivers the equivalent of valsartan 160 mg twice 
daily and significant and sustained neprilysin inhibition.
Definition of Pre–Diabetes Mellitus, Undiagnosed 
Diabetes Mellitus, and Diabetes Mellitus
For the purposes of this study, patients without a previous diagno-
sis of diabetes mellitus were divided into 3 categories according to 
the hemoglobin A1c (HbA1c) level using the International Diabetes 
Expert Committee criteria14,15: (1) normal, <6.0% (<42 mmol/mol); 
(2) pre–diabetes mellitus, 6.0% to 6.4% (42–47 mmol/mol); and (3) 
undiagnosed diabetes mellitus, ≥6.5% (≥48 mmol/mol). Patients with 
a previous diagnosis of diabetes mellitus (irrespective of HbA1c lev-
el) were considered to have diabetes mellitus.
Study Outcomes
The PARADIGM-HF trial was designed to recruit ≈8400 patients and 
continue until 1229 patients experienced cardiovascular deaths and 2410 
patients experienced either a first hospitalization for heart failure or car-
diovascular death (primary outcome). However, an independent data and 
safety monitoring board recommended early termination of the study 
when the prespecified boundary for overwhelming benefit for both car-
diovascular mortality and the primary outcome had been crossed. The 
primary outcome of this analysis was a composite of death from cardio-
vascular causes or a first hospitalization for heart failure. The secondary 
outcomes of the PARADIGM-HF trial were the time to death from any 
cause, the change from baseline to 8 months in the clinical summary 
score on the Kansas City Cardiomyopathy Questionnaire (KCCQ; on a 
scale from 0 to 100, with higher scores indicating fewer symptoms and 
physical limitations associated with heart failure), the time to a new on-
set of atrial fibrillation, and the time to the first occurrence of a decline 
in renal function (which was defined as end-stage renal disease or as a 
decrease in the eGFR of at least 50% or a decrease of >30 mL/min per 
1.73 m2 from randomization to <60 mL/min per 1.73 m2); there were too 
few patients with new onset atrial fibrillation and decline in renal func-
tion for meaningful analysis in the current study of HbA1c subgroups. 
Adjudication of these outcomes was carried out in a blinded fashion by 
a clinical end point committee according to pre–specified criteria. Safety 
outcomes included hypotension, elevation of serum creatinine, hyperka-
lemia, cough, and angioedema, as previously reported.11
Statistical Analysis
Baseline characteristics are presented as mean with SDs for con-
tinuous variables and frequencies and percentages for categorical 
variables. Unadjusted event rates are reported per 100 patient-years 
of follow-up according to diabetic status. Cox proportional hazard 
models were applied to calculate hazard ratios (HRs) for the out-
comes in patients with pre–diabetes mellitus, undiagnosed diabe-
tes mellitus, and diabetes mellitus with normoglycemic patients as 
reference, as well as treatment effect of LCZ696 for the outcomes 
according to glycemic status. Event-free survival curves (Figure 1) 
were calculated using Kaplan–Meier estimates. In additional Cox 
models, we examined the relationship between diabetic status and 
outcomes stratified by EF and kidney function (Figures 2 and 3). The 
adjusted Cox regression models included information on age, sex, 
race (white versus all other), geographical region, heart failure dura-
tion, New York Heart Association class, EF, heart rate, KCCQ score, 
body mass index, eGFR, N-terminal pro-BNP, ischemic cause, and 
history of myocardial infarction, stroke, and atrial fibrillation. We 
compared the frequency of a ≥5-point decline in the KCCQ score 
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at 8-month follow-up according to diabetes mellitus status and used 
logistic regression to calculate odds ratios for this reduction in pa-
tients with diabetes mellitus and pre–diabetes mellitus compared with 
normoglycemic patients. We applied a cubic spline model to assess 
the relationship between HbA1c and the primary composite outcome 
in patients not treated with glucose-lowering drugs. All P values are 
2-sided, and a P value of <0.05 was considered significant. Analyses 
were performed using Stata version 13 (Stata Corp, College Station, 
TX), and SAS version 9.4 (SAS Institute, Cary, NC).
Results
Overall, 8274 patients had known diabetes mellitus or a mea-
surement of HbA1c at baseline. Of these, 2907 (35%) had a 
history of diabetes mellitus. Of the 5367 (65%) patients with 
no history of diabetes mellitus, 2160 (40% [26% of total]) had 
HbA1c <6.0%, 2103 (39% [25% of total]) had HbA1c 6.0% 
to <6.5%, and 1106 (21% [13% of total]) had HbA1c ≥6.5% 
(“undiagnosed diabetes mellitus”). A total of 4013 (49%) 
patients were, therefore, defined as having diabetes mellitus 
based on history (n=2907) or HbA1c ≥6.5% (n=1106). The 
median follow-up in patients with normal HbA1c was 26 
months, and it was 27 months in both patients with pre–diabe-
tes mellitus and diabetes mellitus.
Baseline Characteristics
Patients with pre–diabetes mellitus and diabetes mellitus were 
older, more often whites, had longer heart failure duration, a 
higher body mass index (and more obesity), and evidence of 
overall worse heart failure status (Table 1). Manifestations of 
worse heart failure status included higher New York Heart Asso-
ciation class and BNP levels, lower KCCQ score and eGFR, 
more edema, and greater use of diuretics (Table 1). The excep-
tion to this was EF, which was marginally although insignifi-
cantly higher in patients with pre–diabetes mellitus and diabetes 
mellitus compared with those with normal HbA1c. Patients with 
pre–diabetes mellitus and diabetes mellitus also more com-
monly had a history of myocardial infarction and atrial fibril-
lation. Generally, the trends identified were most marked in 
patients with diabetes mellitus and intermediate between diabe-
tes mellitus and normoglycemia in individuals with pre–diabetes 
mellitus. Patients in Latin America had the lowest prevalence of 
pre–diabetes mellitus/diabetes mellitus and the highest propor-
tion of normoglycemia. The prevalence of diabetes mellitus was 
most prevalent in North America and the Asia-Pacific region. 
However, when both diabetes mellitus and pre–diabetes mellitus 
were taken into account, the rate of dysglycemia was similar in 
Western/Central Europe and the Asia-Pacific region and less in 
North America, compared with these other regions.
Clinical Outcomes According to HbA1c Category 
and Diabetes Mellitus Status
The clinical outcomes of interest according to the predefined 
glycemia categories are summarized in Table 2 and illustrated 
Figure 1. Kaplan–Meier curves for the primary composite end point of cardiovascular death or heart failure (HF) hospitalization, each of 
the components separately, and all-cause mortality according to history of diabetes mellitus and glycemic status. HbA1c indicates hemo-
globin A1c.
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in Figure 1. The rates of both the primary composite outcome 
and all-cause death were the lowest in the normal HbA1c 
group, significantly higher in the pre–diabetes mellitus cat-
egory, and the highest in individuals with undiagnosed and 
known diabetes mellitus (Table 2; Figure 1). Patients with 
a history of diabetes mellitus were at higher risk of the pri-
mary composite outcome of heart failure hospitalization and 
cardiovascular mortality compared with those with normal 
HbA1c: adjusted HR, 1.64; 95% confidence interval, 1.44 
to 1.88; P<0.001. The HR for patients with undiagnosed 
Figure 2. Relationship between ejection fraction (EF) and the primary outcome stratified by history of diabetes mellitus (DM) and glycemic 
status. CI indicates confidence interval; HbA1c, hemoglobin A1c; and HR, hazard ratio.
Figure 3. Relationship between diabetic status and the primary outcome stratified by kidney function. DM indicates diabetes mellitus; 
eGFR, estimated glomerular filtration rate; and HbA1c, hemoglobin A1c.
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Table 1. Baseline Characteristics According to the Presence of Diabetes Mellitus, Defined by Previous Diagnosis, 
Undiagnosed Diabetes Mellitus (HbA1c, ≥6.5), Pre–Diabetes Mellitus (HbA1c, 6.0–6.4), or Normoglycemia (HbA1c, <6.0)
No Previous Diagnosis of Diabetes Mellitus Previous Diabetes Mellitus
P ValueHbA1c, <6.0 HbA1c, 6.0–6.4 HbA1c, >6.4 Any HbA1c
Patients, n (%) 2158 (26) 2103 (26) 1106 (13) 2907 (35) …
Age, mean 62±12 64±12 63±12 65±10 <0.0001
Women, n (%) 474 (22) 470 (22) 258 (23) 613 (21) 0.4429
White, n (%) 1333 (62) 1424 (68) 688 (62) 2010 (69) <0.0001
LCZ696 treatment, n (%) 1087 (50) 1040 (50) 549 (50) 1451 (50) 0.9426
HbA1c, median (Q1–Q3) 5.6 (5.4–5.7) 6.1 (6.0–6.2) 6.6 (6.5–6.9) 7.2 (6.5–8.4) <0.0001
HF duration, y, n (%)
  0–1 707 (33) 629 (30) 379 (34) 765 (26) <0.0001
  >1–5 841 (39) 834 (40) 414 (38) 1106 (38)
  >5 610 (28) 640 (30) 313 (28) 1036 (36)
NYHA class, n (%)
  I 109 (5) 102 (5) 56 (5) 115 (4) <0.0001
  II 1614 (75) 1474 (70) 750 (68) 1996 (69)
  III 420 (19) 502 (24) 294 (27) 770 (26)
  IV 10 (1) 22 (1) 4 (0) 24 (1)
Geographical region, n (%)
  North America 185 (30) 102 (17) 27 (4) 299 (49) <0.0001
  Latin America 512 (37) 345 (25) 154 (11) 385 (28)
  Western Europe 431 (23) 529 (28) 260 (14) 678 (36)
  Central Europe 670 (24) 758 (27) 397 (14) 962 (35)
  Asia-Pacific 360 (23) 369 (23) 268 (17) 583 (37)
Jugular venous distension, n (%) 199 (9) 199 (10) 120 (11) 289 (10) 0.4738
Edema, n (%) 363 (17) 444 (21) 234 (21) 688 (24) <0.0001
Rales, n (%) 139 (6) 170 (8) 92 (8) 252 (9) 0.0287
Third heart sound, n (%) 199 (9) 176 (8) 121 (11) 290 (10) 0.0810
Ejection fraction 0.29±0.06 0.30±0.06 0.29±0.06 0.30±0.06 0.0338
Heart rate, beats per min 71±12 72±12 73±13 74±12 <0.0001
SBP, mm Hg 121±15 120±15 120±14 123±16 <0.0001
KCCQ score 76±18 73±19 72±19 71±20 <0.0001
BMI, kg/m2, n (%)
<18 9 (0) 18 (1) 10 (1) 9 (0) <0.0001
18–24.9 607 (28) 502 (31) 220 (20) 433 (15)
25–29.9 935 (43) 833 (40) 447 (40) 1040 (36)
30 607 (28) 750 (36) 429 (39) 1425 (49)
eGFR, mL/min per 1.73 m2 69 (56–82) 66 (54–78) 66 (54–80) 64 (52–78) <0.0001
CKD (eGFR<60), n (%) 686 (32) 753 (36) 401 (36) 1183 (41) <0.0001
BNP, pg/mL 240 (143–443) 251 (157–496) 291 (172–582) 247 (154–449) <0.0001
NT-proBNP, pg/mL 1582 (878–3036) 1664 (906–3326) 1838 (954–3758) 1549 (854–3103) <0.0001
ICD/CRT-D, n (%) 321 (15) 292 (14) 113 (10) 501 (17) <0.0001
CRT-P+D, n (%) 152 (7) 129 (6) 54 (5) 232 (8) 0.0025
Medical history, n (%)
  Ischemic cause 1117 (52) 1207 (57) 659 (60) 1980 (68) <0.0001
  Previous MI 814 (38) 848 (40) 454 (41) 1459 (50) <0.0001
  Previous stroke 180 (8) 178 (9) 69 (6) 286 (10) 0.0033
  Previous AF 697 (32) 827 (39) 436 (39) 1072 (37) <0.0001
Medication, n (%)
  Loop diuretic 1628 (75) 1644 (78) 933 (84) 2434 (84) <0.0001
(Continued)
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diabetes mellitus (HbA1c, >6.5%) compared with those with 
HbA1c <6.0% was 1.39 (1.18–1.64); P<0.001. The elevation 
in risk related to dysglycemia seemed more marked for heart 
failure hospitalization than for cardiovascular death or all-
cause death. These differences in risk persisted after adjust-
ing for other prognostic variables. In particular, the elevated 
Table 2. Event Rates and Risks of the Primary End Point (CV Death or Heart Failure Hospitalization), CV Death, Heart Failure 
Hospitalization, All-Cause Mortality, and Worsening KCCQ Score, According to History of DM and Glycemic Status
No. of Patients No. of Events Crude Rate per 100 py Unadjusted Hazard Ratio Adjusted* Hazard Ratio P Value
Primary composite end point
No DM and HbA1c, <6.0 2158 388 8.52 (7.72–9.43) 1.00 (reference) 1.00 (reference) …
No DM and HbA1c, 6.0–6.4 2103 478 10.88 (9.94–11.90) 1.28 (1.12–1.46) 1.28 (1.11–1.47) 0.001
No DM and HbA1c, ≥6.5 1106 289 12.87 (11.47–14.45) 1.51 (1.30–1.76) 1.39 (1.18–1.64) <0.001
DM and any HbA1c 2907 851 14.84 (13.88–15.88) 1.73 (1.54–1.95) 1.64 (1.44–1.88) <0.001
CV death
No DM and HbA1c, <6.0 2158 249 5.25 (4.64–5.94) 1.00 (reference) 1.00 (reference) …
No DM and HbA1c, 6.0–6.4 2103 302 6.46 (5.77–7.23) 1.23 (1.04–1.45) 1.29 (1.07–1.54) 0.006
No DM and HbA1c, ≥6.5 1106 189 7.80 (6.76–8.99) 1.49 (1.23–1.79) 1.37 (1.11–1.69) 0.004
DM and any HbA1c 2907 496 7.76 (7.11–8.47) 1.48 (1.27–1.72) 1.54 (1.30–1.83) <0.001
Heart failure hospitalization
No DM and HbA1c, <6.0 2158 201 4.42 (3.85–5.07) 1.00 (reference) 1.00 (reference) …
No DM and HbA1c, 6.0–6.4 2103 265 6.03 (5.35–6.80) 1.37 (1.14–1.64) 1.33 (1.09–1.61) 0.006
No DM and HbA1c, ≥6.5 1106 170 7.57 (6.52–8.80) 1.72 (1.40–2.11) 1.54 (1.23–1.92) <0.001
DM and any HbA1c 2907 543 9.47 (8.71–10.30) 2.13 (1.81–2.51) 1.90 (1.59–2.27) <0.001
All-cause mortality
No DM and HbA1c, <6.0 2158 321 6.77 (6.07–7.55) 1.00 (reference) 1.00 (reference) …
No DM and HbA1c, 6.0–6.4 2103 373 7.97 (7.20–8.82) 1.18 (1.01–1.37) 1.22 (1.03–1.51) 0.015
No DM and HbA1c, ≥6.5 1106 218 9.00 (7.88–10.27) 1.33 (1.12–1.58) 1.25 (1.03–1.51) 0.022
DM and any HbA1c 2907 613 9.59 (8.86–10.38) 1.42 (1.24–1.62) 1.46 (1.26–1.70) <0.001
Significant worsening in KCCQ clinical score (≥5) at 8 mo†
No DM and HbA1c, < 6.0 1958 559 1.00 (reference) 1.00 (reference) …
No DM and HbA1c, 6.0–6.4 1921 582 1.09 (0.95–1.26)‡ 1.04 (0.91–1.20)‡ 0.560
No DM and HbA1c, ≥6.5 977 312 1.17 (0.99–1.39)‡ 1.12 (0.95–1.33)‡ 0.187
DM and any HbA1c 2650 917 1.33 (1.17–1.51)‡ 1.23 (1.07–1.40)‡ 0.003
CV indicates cardiovascular; DM, diabetes mellitus; HbA1c, hemoglobin A1c; and KCCQ, Kansas City Cardiomyopathy Questionnaire.
*Adjusted for age, sex, race (white vs all other), geographical region, heart failure duration, New York Heart Association class, left ventricular ejection fraction, heart 
rate, KCCQ score, body mass index, estimated glomerular filtration rate, N-terminal pro–B-type natriuretic peptide, ischemic cause, previous myocardial infarction, 
previous stroke, and previous atrial fibrillation.
†Scores on the KCCQ range from 0 to 100 (higher scores indicating fewer symptoms).
‡Effect of diabetes mellitus/dysglycemia on worsening KCCQ clinical score (≥5) at 8 mo was estimated by logistic regression and is shown as odds ratios. Information 
on KCCQ score was only available for 7623 (92%) patients.
  Digoxin 610 (28) 645 (31) 370 (34) 882 (30) 0.0226
  β-blocker 2014 (93) 1958 (93) 1021 (92) 2704 (93) 0.7566
  MRA 1224 (57) 1175 (56) 643 (58) 1562 (54) 0.0431
  Statin 1041 (48) 1106 (53) 589 (53) 1916 (66) <0.0001
  Antiplatelets, any 1151 (53) 1124 (53) 582 (53) 1797 (62) <0.0001
  Insulin 0 0 0 722 (25) <0.0001
  Hypoglycemic agent 3 (0.1) 5 (0.2) 4 (0.4) 1779 (61) <0.0001
AF indicates atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; CRT-P+D, cardiac resynchronization therapy, pacemaker + 
defribrillator; HbA1c, hemoglobin A1c; HF, heart failure; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter defribrillator; KCCQ, 
Kansas City Cardiomyopathy Questionnaire; MI, myocardial infarction; MRA, magnetic resonance angiogram; NT-proBNP, N-terminal pro–B-type 
natriuretic peptide; NYHA, New York Heart Association; and SBP, systolic blood pressure.
Table 1. Continued
No Previous Diagnosis of Diabetes Mellitus Previous Diabetes Mellitus
P ValueHbA1c, <6.0 HbA1c, 6.0–6.4 HbA1c, >6.4 Any HbA1c
7  Kristensen et al  Pre–Diabetes Mellitus and Diabetes Mellitus in PARADIGM-HF
risk related to pre–diabetes mellitus and diabetes mellitus was 
apparent across the spectrum of EF, although nonsignificantly 
so in patients with EF >35% and tended to be accentuated at 
lower EF (Figure 2). A similar pattern was observed when we 
assessed the risk related to diabetes mellitus and pre–diabetes 
mellitus according to kidney function (Figure 3). In a cubic 
spline analysis restricted to patients not on glucose-lowering 
drugs (n=6069), we found a correlation between increasing 
HbA1c and elevated risk of the primary outcome (Figure 4).
At 8 months after randomization, more patients with 
known diabetes mellitus (35%) and undiagnosed diabetes 
mellitus (32%) had a decline of ≥5 points in KCCQ score, 
compared with patients with pre–diabetes mellitus (30%) and 
those with normal HbA1c (29%); P value for difference is 
0.0002. Compared with the group with normal HbA1c, the 
adjusted odds ratios for a 5-point reduction were 1.23 (1.07–
1.40) for patients with known diabetes mellitus, 1.12 (0.95–
1.33) for those with undiagnosed diabetes mellitus, and 1.04 
(0.91–1.20) for patients with pre–diabetes mellitus (Table 2).
Effect of LCZ696 (Sacubitril/Valsartan) According 
to Diabetes Mellitus Status
The effect of LCZ696 on the different outcomes is shown 
in Table 3. In each of the 3 predefined glycemia categories, 
LCZ696 reduced the occurrence of the primary composite 
outcome compared with enalapril. Fewer patients treated with 
LCZ696 considered themselves worse 8 months into the study 
(defined by a reduction in KCCQ score of ≥5 points) in all 4 
predefined glycemia categories, with no significant interaction 
between glycemia category and treatment (P=0.14).
Prespecified Safety Assessments
Adverse events causing drug discontinuation were overall rare, 
although more prevalent in patients with diabetes mellitus, 
compared with patients with normal HbA1c, and intermediate 
in the pre–diabetes mellitus group (Table 4). Renal impair-
ment and hyperkalemia were more prevalent adverse events in 
patients with diabetes mellitus. We found no interaction with 
LCZ696 treatment, except for a higher likelihood of increase 
in serum creatinine ≥3.0 mg/dL, but importantly, this did not 
lead to more study drug discontinuation. Angioedema was 
very rare, regardless of diabetic status and assigned treatment.
Patients With Previously Known Diabetes Mellitus 
Versus Undiagnosed Diabetes Mellitus
Notable differences between these 2 groups included older 
age, longer duration of heart failure, lower eGFR, and more 
frequent ischemic cause (and previous myocardial infarction), 
in patients with known diabetes mellitus (Table 1). In terms of 
medication, patients with known diabetes mellitus were more 
likely to be treated with antiplatelet agents and statins. The 
risk of the primary outcome was higher in patients with known 
diabetes mellitus (P=0.025), primarily because of a higher 
risk of heart failure hospitalization (P=0.032), whereas the 
risk of cardiovascular death was similar in those with known 
and undiagnosed diabetes mellitus (P=0.205). Finally, the risk 
of all-cause mortality seemed higher in patients with known 
diabetes mellitus, compared with patients with HbA1c ≥6.5%, 
and more so in adjusted analyses (HR, 1.46 [1.26–1.70] versus 
HR, 1.25 [1.03–1.51]; P=0.07).
Discussion
This study has 3 key findings. First, although it is known 
that the prevalence of diabetes mellitus is high in patients 
with HF-REF, it seems that both pre–diabetes mellitus and 
undiagnosed diabetes mellitus are also common in these 
patients. Second, non–diabetic dysglycemia (pre–diabetes 
mellitus) is associated with a substantially increased risk of 
adverse outcomes in HF-REF. Finally, LCZ696 (sacubitril/
valsartan) is superior to enalapril, irrespective of glycemic 
status.
The first of our findings shows that a patient with HF-REF 
without a history of diabetes mellitus has approximately a 
1-in-5 chance of actually having the condition (but not yet diag-
nosed) and a >1-in-3 chance of having pre–diabetes mellitus, 
based on HbA1c testing. Few previous studies have reported 
the prevalence of non–diabetic dysglycemia in HF-REF. In 1 
seminal report, describing a substudy of 663 patients in the 
Randomized Evaluation of Strategies for Left Ventricular 
Dysfunction (RESOLVD) pilot study,16 27% had known diabe-
tes mellitus. Among the remaining patients, 11% had undiag-
nosed diabetes mellitus (fasting plasma glucose, ≥7.1 mmol/L) 
and 12% a fasting glucose between 6.1 and 7.1 mmol/L diag-
nostic of the pre–diabetic condition impaired fasting glycemia. 
Egstrup et al17 used the more sensitive approach of oral glucose 
tolerance testing to explore the same question in 227 ambula-
tory patients with HF-REF without known diabetes mellitus 
attending a heart failure clinic in Denmark. Of these, 60% had 
normal glucose tolerance, 22% impaired glucose tolerance, 
and 18% undiagnosed diabetes mellitus (an additional 20% of 
the study cohort had known diabetes mellitus). Among patients 
without diabetes mellitus in our much larger and geographi-
cally diverse population, the proportions of patients with pre–
diabetes mellitus (38%) and undiagnosed diabetes mellitus 
(20%) were both higher. The overall prevalence of diabetes 
mellitus and pre–diabetes mellitus was, therefore, a remark-
able 74%. We found some geographic variation in prevalence, 
with patients from Latin America having the lowest prevalence 
Figure 4. Risk of the primary composite outcome according 
to hemoglobin A1c (HbA1c) in patients not receiving glucose-
lowering drugs.
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of dysglycemia and patients in the Asia-Pacific region and 
Europe the highest. This contrasts strikingly with the preva-
lence of diabetes mellitus in the general population. For exam-
ple, using similar HbA1c diagnostic thresholds, the prevalence 
of diagnosed diabetes mellitus, undiagnosed diabetes mellitus, 
and pre–diabetes mellitus in US residents aged ≥65 years was 
17.7% (95% confidence interval, 15.6–19.8), 3.5% (2.6–4.4), 
and 8.1% (6.6–9.6), respectively, giving a total of 29.3% indi-
viduals with diabetes mellitus or pre–diabetes mellitus, an 
overall prevalence considerably less than half of that observed 
in our patients with HF-REF.18
The significance of this finding is related to the worse clin-
ical status and substantially elevated risk of adverse clinical 
outcomes conferred by both pre–diabetes mellitus and diabetes 
mellitus. In 1 study, pre–diabetes mellitus and insulin resistance 
were correlated with worse symptom status, reduced exercise 
tolerance, and neurohumoral activation, and another study 
showed that elevated HbA1c was associated with increased 
mortality in nondiabetic patients referred for suspected heart 
failure.19,20 Our findings confirm and extend these previous 
observations from RESOLVD pilot study, particularly with 
the demonstration of a worse KCCQ score, more edema and 
Table 3. Treatment Effects of LCZ696 (Sacubitril/Valsartan) According to History of Diabetes Mellitus and Glycemic Status
Overall Normoglycemia
Pre–Diabetes  
Mellitus
Undiagnosed  
Diabetes Mellitus Diabetes Mellitus P Values for 
InteractionHR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
HF hospitalization or cardiovascular death 0.80 (0.73–0.87) 0.68 (0.56–0.83) 0.76 (0.63–0.91) 0.97 (0.77–1.22) 0.87 (0.77–0.98) 0.13
Cardiovascular death 0.80 (0.71–0.89) 0.62 (0.48–0.80) 0.76 (0.61–0.96) 0.86 (0.65–1.15) 0.92 (0.77–1.09) 0.09
HF hospitalization 0.80 (0.71–0.89) 0.85 (0.65–1.12) 0.73 (0.57–0.93) 0.88 (0.65–1.20) 0.79 (0.67–0.94) 0.78
All-cause mortality 0.84 (0.76–0.93) 0.68 (0.55–0.85) 0.77 (0.63–0.95) 0.91 (0.69–1.18) 0.97 (0.83–1.14) 0.06
Significant worsening in KCCQ clinical score 
(≥5) at 8 mo†
0.83(0.76–0.92)‡ 0.73 (0.60–0.89)‡ 0.86 (0.71–1.04)‡ 0.93 (0.71–1.21)‡ 0.86 (0.74–1.01)‡ 0.14
CI indicates confidence interval; HF, hear failure; HR, heart rate; and KCCQ, Kansas City Cardiomyopathy Questionnaire.
†Scores on the KCCQ range from 0 to 100 (higher scores indicating fewer symptoms).
‡Treatment effect of LCZ696 (sacubitril/valsartan) on worsening KCCQ clinical score (≥5) at 8 mo was estimated by logistic regression and is shown as odds ratios. 
Information on KCCQ score was only available for 7623 (92%) patients.
Table 4. Prespecified Safety Assessments According to History of Diabetes Mellitus and Glycemic Status
Normal HbA1c,  
n=2158
Pre–Diabetes  
Mellitus, n=2103
Undiagnosed 
Diabetes  
Mellitus, n=1106
Diabetes  
Mellitus, n=2907 P Values of 
InteractionEnalapril LCZ696 Enalapril LCZ696 Enalapril LCZ696 Enalapril LCZ696
Hypotension, n (%)
  Symptomatic hypotension 98 (9) 160 (15) 88 (8) 173 (17) 46 (8) 57 (10) 149 (10) 191 (13) 0.051
  Symptomatic hypotension with SBP <90 mm Hg 15 (1) 28 (3) 12 (1) 37 (4) 8 (1) 11 (2) 23 (2) 34 (2) 0.296
  Leading to study drug discontinuation 5 (1) 10 (1) 7 (1) 9 (1) 5 (1) 5 (1) 11 (1) 11 (1) 0.336
Renal impairment, n (%)
  Serum creatinine, ≥2.5 mg/dL 29 (3) 28 (3) 35 (3) 29 (3) 21 (4) 16 (3) 102 (7) 65 (5) 0.126
  Serum creatinine, ≥3.0 mg/dL 13 (1) 15 (1) 8 (1) 15 (1) 8 (1) 8 (2) 53 (4) 25 (2) 0.029
  Leading to study drug discontinuation 9 (1) 5 (1) 12 (1) 2 (0) 8 (1) 6 (1) 30 (2) 16 (1) 0.594
Hyperkalemia, n (%)
  Serum potassium, >5.5 mmol/L 149 (14) 151 (14) 167 (16) 143 (14) 83 (15) 94 (17) 319 (22) 281 (19) 0.488
  Serum potassium, >6.0 mmol/L 54 (5) 40 (4) 54 (5) 38 (4) 26 (5) 25 (5) 100 (7) 77 (5) 0.738
  Leading to study drug discontinuation 2 (0) 1 (0) 2 (0) 1 (0) 3 (1) 3 (1) 8 (1) 6 (0) 0.744
Cough, n (%)
  Any cough 143 (13) 116 (11) 150 (14) 121 (12) 82 (15) 70 (13) 220 (15) 160 (11) 0.697
  Leading to study drug discontinuation 5 (1) 1 (0) 9 (1) 3 (0) 1 (0) 2 (0) 15 (1) 2 (0) 0.737
Angioedema (adjudicated), n (%)
  No treatment or antihistamines only 4 (0) 4 (0) 2 (0) 3 (0) 1 (1) 2 (0) 0 (0) 2 (0) 0.360
  Catecholamines or corticosteroids without hospitalization 0 (0) 1 (0) 3 (0) 3 (0) 1 (1) 0 (0) 0 (0) 2 (0) 0.741
  Hospitalized without airway compromise 0 (0) 1 (0) 1 (0) 2 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.779
  Airway compromise 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) …
Any adverse event leading to study drug discontinuation, n (%) 21 (2) 15 (1) 30 (3) 15 (1) 16 (3) 14 (3) 61 (4) 34 (3) 0.905
HbA1c indicates hemoglobin A1c; and SBP, systolic blood pressure.
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higher natriuretic peptide levels in patients with pre–diabetes 
mellitus compared with those with normal HbA1c.16 The find-
ing that lower HbA1c in patients without known diabetes mel-
litus corresponded to a better prognosis is in contrast with the 
observed U-shaped relationship between HbA1c and adverse 
outcomes in patients with known and treated diabetes melli-
tus.21 We also found, as previously, that these manifestations 
of worse clinical status were apparent despite a similar or even 
higher EF than in the group with normal HbA1c, which is an 
unexplained and perhaps paradoxical finding.
Although the heightened risk related to diabetes mellitus 
is well known, the risk associated with pre–diabetes melli-
tus is not. This finding is important for many reasons. Most 
significantly, it shows that dysglycemia itself, rather than the 
use of hypoglycemic drugs, is a risk factor for adverse out-
comes. Recently, there has been concern that the agents used 
to lower blood glucose may be harmful in patients with heart 
failure.3,22,23 As our patients with pre–diabetes mellitus were 
not receiving these treatments, hypoglycemic agents cannot 
account for the worse outcomes in this group compared with 
subjects with normal HbA1c. However, patients with diabe-
tes mellitus also did worse than patients with pre–diabetes 
mellitus (and those with known diabetes mellitus did worse 
than those with undiagnosed diabetes mellitus), still leaving 
open the possibility of harm related to hypoglycemic drugs 
(although there are other reasons why the more severe and 
probably longer duration of hyperglycemia in diabetes mel-
litus might be associated with worse outcomes than pre–dia-
betes mellitus).
Second, these findings are important as they emphasize 
the need to better understand the effect of treatments for 
dysglycemia on outcomes in patients with heart failure. If 
hypoglycemic treatments were shown to improve outcomes 
across the range of dysglycemia, including both pre–diabetes 
mellitus and diabetes mellitus, potentially a large proportion 
of patients would be eligible for such treatment. Although 
the relationship between dysglycemia and adverse events in 
heart failure is clear and strong, it is only an association and a 
clear cause-and-effect mechanistic pathway has not been con-
firmed. Moreover, as alluded to above, there has been concern 
that at least some hypoglycemic agents may increase rather 
than decrease the risk of heart failure–related events.23
As anticipated, renal dysfunction and hyperkalemia 
were more common among patients with diabetes mellitus 
(compared with those with normoglycemia) in the enalapril 
group; however, both these adverse effects were numerically 
(but statistically insignificantly) less common in the LCZ696 
group, compared with the enalapril group, across all glyce-
mia categories. Renal dysfunction was also more frequent in 
angiotensin-converting enzyme inhibitor–treated patients with 
diabetes mellitus than in those without diabetes mellitus.24 
Marked renal dysfunction (serum creatinine, ≥3.0 mg/dL) was 
less frequent with LCZ696 than with enalapril, irrespective of 
glycemia status. Hypotension was more common overall with 
LCZ696 compared with enalapril; the increment in hypoten-
sion with LCZ696 was smaller in patients with diabetes mel-
litus than in the other glycemia groups.
This study has many limitations. It is a retrospective 
analysis. Our dysglycemia categorization is based on 1 set 
of criteria, and other slightly different criteria exist.25,26 Our 
patients had only 1 measurement of HbA1c and not at least 2 
measurements or supplementary analyses of fasting glucose 
and oral glucose tolerance, as recommended in guidelines.14,15
In summary, we have shown that in patients with chronic 
HF-REF, dysglycemia is common and pre–diabetes mellitus, 
as well as diabetes mellitus, is associated with worse clini-
cal status and a significantly increased risk of adverse cardio-
vascular outcomes compared with normoglycemic patients. 
LCZ696 was beneficial, irrespective of HbA1c concentration 
and diabetes mellitus status.
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CLINICAL PERSPECTIVE
In this study, we examined the prevalence of pre–diabetes mellitus and diabetes mellitus in patients with heart failure and 
reduced ejection fraction in the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and 
Morbidity in Heart Failure (PARADIGM-HF) trial and their relationship with clinical outcomes. We also examined whether 
dysglycemia modified the benefit of sacubitril/valsartan compared with enalapril. Pre–diabetes mellitus (25% of patients), 
undiagnosed diabetes mellitus (13%), and known diabetes mellitus (35%) were common and associated with worse symp-
toms, more edema, and higher natriuretic peptide levels than normoglycemia. Patients with dysglycemia had a higher risk 
of cardiovascular death and heart failure hospitalization. The benefit of sacubitril/valsartan was consistent irrespective of 
glycemic status. These findings confirm and extend previous observations that patients with pre–diabetes mellitus and dia-
betes mellitus have worse clinical status and outcomes than normoglycemic patients, despite similar or higher ejection frac-
tion. In particular, the observation that untreated dysglycemia is associated with adverse outcomes is notable. The potential 
mechanistic pathway(s) linking dysglycemia to adverse outcomes in heart failure and reduced ejection fraction remain to be 
elucidated, as do the effects of hypoglycemic agents in the large segment of these patients with pre–diabetic dysglycemia.
